AbbVie Inc. (ABBV) vs ELI LILLY & Co (LLY)
Side-by-side comparison from SEC filings: latest annual financials, insider activity and institutional ownership.
| Metric | ABBV | LLY |
|---|---|---|
| Sector | Health Care | Health Care |
| Latest fiscal year | FY2025 | FY2025 |
| Revenue | $61.16B | $65.18B |
| Revenue growth (YoY) | ▲ 8.6% | ▲ 44.7% |
| Net income | $4.23B | $20.64B |
| Gross margin | 70.2% | 83.0% |
| Diluted EPS | $2.36 | $22.95 |
| Insider net (6 mo) | +12.3K sh • 1 sells • 0 buys | −31.3K sh • 5 sells • 0 buys |
| Institutional owners | 46 | 51 |
| Institutional value held | $222.87B | $533.23B |
| Next earnings (est.) | Around Feb 3, 2027 | Around Oct 29, 2026 |
Figures from each company's SEC filings (latest reported fiscal year; fiscal calendars may differ). Next-earnings dates are estimates from historical filing patterns.
About AbbVie Inc. (ABBV)
AbbVie Inc., incorporated in Delaware in 2012, is a global, diversified research-based biopharmaceutical company that became an independent, publicly-traded entity on January 1, 2013, following its spin-off from Abbott Laboratories. Read more →
About ELI LILLY & Co (LLY)
Eli Lilly and Company, incorporated in Indiana in 1901 and tracing its roots to a drug manufacturing business founded in 1876, operates as a single-segment human pharmaceutical company focused on discovering, developing, manufacturing, and marketing… Read more →
Source: SEC EDGAR.